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 Abstract  Bullous pemphigoid (BP) is the most common autoimmune blistering 
disorder. BP autoantibodies target two hemidesmosomal components, collagen 
XVII (COL17) and BP230, with autoimmunity to COL17 being mainly involved in 
the development of the disease. BP most commonly affects the elderly, and systemic 
corticosteroids are widely used to treat blisters on the entire body. Therefore, severe 
cases are sometimes fatal. Toward developing innovative, disease-speciﬁ c therapies 
with fewer adverse effects, faithful disease models are essential. However, it has 
been challenging to reproduce BP in animals, because of inter-species differences in 
the amino acid sequences of pathological epitopes on human and mouse COL17. 
Human IgG autoantibodies from BP patients are unable to bind with mouse COL17; 
thus, the passive transfer of BP-IgG into mice fails to induce blistering disease. To 
overcome inter-species differences, we have generated genetically modiﬁ ed mice 
that express human but not mouse COL17 in skin. We call these “COL17-humanized 
mice”. Using these mice, we have produced different BP models to elucidate the BP 
pathomechanism and to produce novel BP therapies. Currently, another novel model 
is under development. Here, we introduce the BP models that we have developed by 
using a novel technique called “humanization of autoantigen”. 
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 Bullous Pemphigoid (BP), The Most Common Autoimmune 
Blistering Disease 
 Clinical Features of BP 
 Bullous pemphigoid (BP) is the most common autoimmune blistering skin disorder, 
and the elderly are the most prone to it [ 1 ,  2 ]. In typical cases of BP, urticarial erythe-
mas with tense blisters on the trunk and extremities associated with pruritus are 
observed (Fig.  1a ). BP usually develops around the seventh to eighth decades of life in 
both sexes. Individuals younger than age 50 rarely develop BP. Previous retrospective 
studies in European countries have shown a prevalence of around 6.6:1,000,000 per 
year, but recent analyses have shown an increased prevalence of 21.7 ~ 66:1,000,000 
[ 3 ]. This increase is probably due to population aging and to development of diagnostic 
tools such as ELISA assays that can easily detect circulating autoantibodies (autoAbs).
 Pathogenesis of BP 
 Direct immunoﬂ uorescence (IF) studies of the perilesional skin shows linear in vivo 
deposition of IgG and C3 at the dermal–epidermal junction (DEJ) (Fig.  1b ), and cir-
culating IgG autoAbs binding the DEJ of the skin can be found in sera from BP 
 Fig. 1  Clinical and immunopathological manifestations of BP. ( a ) Urticarial erythema with tense 
blisters. ( b ) DIF studies of the lesional skin show linear in vivo deposition of IgG ( arrowheads ) 
and C3 ( arrows ) at the DEJ. ( c ) COL17 and hemidesmosomal molecules at the DEJ (partially 
modiﬁ ed from Nishie et al. [ 4 ]) 
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patients by indirect IF. The autoAbs in BP patients target two hemidesmosomal 
 components: transmembrane collagen XVII (COL17, also called BP180 or BPAG2) 
and the plakin family protein BP230 (BPAG1) (Fig.  1c ). Of these, COL17 is thought 
to be the major autoantigen (autoAg) [ 4 ]. The IgG autoAbs against the COL17 in the 
DEJ of the skin are considered to trigger the inﬂ ammatory process, resulting in the 
disruption of dermal–epidermal anchoring [ 2 ,  3 ]. It remains uncertain as to whether 
anti-BP230 autoantibodies in BP patients are pathogenic for blister formation or whether 
they are just by-products of epitope-spreading associated with disease extension. 
 COL17 as a Main AutoAg for BP 
 COL17 is a type-II-oriented 1,497-amino-acid transmembrane collagen whose amino 
(N) terminus is in the cytoplasm and whose carboxyl (C) terminus is in the extracel-
lular matrix (ECM) [ 5 ,  6 ]. As described in Fig.  1c , the extracellular domain of COL17 
interacts with laminin 332 and collagen IV in the ECM, and the farthest part of the 
C-terminal region of COL17 has a ﬂ exible tail in vivo [ 7 ]. The extracellular domain 
of COL17 is constitutively cleaved (shed) from the cell surface by ADAM 9/10/17 [ 8 , 
 9 ], a phenomenon that occurs within a juxtamembranous extracellular non-collage-
nous NC16A domain of 77 amino acids. Interestingly, the majority of IgG autoAbs 
from BP patients react with this NC16A domain, and epitopes cluster tightly in the 
N-terminal 45-amino-acid stretch of this region (Fig.  2a ) [ 10 ,  11 ]. These ﬁ ndings 
indicate that autoAbs to the NC16A domain are pathogenic for blister formation in 
BP. However, human IgG autoantibodies from BP patients are unable to bind with 
mouse COL17; thus, the passive transfer of BP-IgG into mice fails to induce blister-
ing disease [ 12 ]. This is attributed to the signiﬁ cant differences between human 
COL17 and mouse COL17 in amino acid sequences of the NC16A domain (Fig.  2a ).
 BP Models Produced by “Humanization of Autoantigen” 
 Generation of COL17-Humanized Mice 
 The pathological relevance of Abs to COL17 has been studied by neonatal mouse 
models that have been produced by injecting rabbit Abs targeting the NC14A domain 
of mouse COL17 (corresponding to NC16A domain of human COL17). When rab-
bit Abs targeting mouse COL17 were passively transferred into wild-type neonatal 
mice, the rabbit Abs bound with the DEJ of the mice skin, after which complement 
activation, mast cell degradation, neutrophil recruitment and, ﬁ nally, epidermal 
detachment by mild friction occurred [ 12 ]. Using the experimental BP model mice 
induced by rabbit IgG against mouse COL17, complement activation followed by 
mast cell degradation and neutrophil inﬁ ltration have been suggested to be involved 
in the blister formation [ 13 – 15 ]. However, the pathogenic relevance of human 
autoAbs to COL17 in BP patients has never been proved. In 2007, our group 
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succeeded in conﬁ rming the pathogenicity of BP autoAbs by using the unique tech-
nique of “humanization of autoantigen” [ 4 ]. First, we generated murine  COL17 - 
knockout (m Col17  −/−  ) mice that developed blisters and erosions on the skin, 
symptoms that reproduce a human disease called non-Herlitz epidermolysis bullosa, 
which is caused by null mutations in the  COL17A1 gene [ 16 ]. Then, we crossed 
 human COL17  +/+   (hCOL17  +/+  ) transgenic (Tg) mice [ 17 ] with heterozygous 
m Col17  +/−  mice. Mice that carried both the heterozygous null mutation of m Col17 
and the transgene of  human COL17 ( mCol17  +/−  , hCOL17  +/−  ) were bred to generate 
COL17-humanized ( hCOL17  +/+  , mCol17  −/−  ) mice (Fig.  2b ). COL17-humanized 
mice lack mouse COL17 but express human COL17. They showed no apparent 
clinical phenotype and were able to deliver COL17-humanized mice pups by mating 
with COL17-humanized mice parents. Neonatal COL17-humanized mice that were 
passively transferred with either total IgG or IgG afﬁ nity-puriﬁ ed against the NC16A 
domain of COL17 from BP patients developed diffuse erythema and showed epider-
mal separation by gentle skin friction at 48 h after transfer (Fig.  2c ) [ 4 ]. Lesional 
skin specimens demonstrated dermal–epidermal separation and inﬂ ammatory cell 
inﬁ ltration of neutrophils and lymphocytes. DIF analysis revealed linear deposition 
of human IgG and mouse C3 at the DEJ, which simulates the human BP phenotype 
(Fig.  2d ). This passive-transfer neonatal mouse model was the ﬁ rst to directly show 
the pathogenicity of anti-COL17 NC16A IgG autoantibodies in BP patients. 
 Fig. 2  Generation of the COL17-humanized mice and a BP model. ( a ) The most pathogenic of the 
epitopes cluster within the juxtamembranous NC16A domain of COL17. Signiﬁ cant differences in 
their amino acid sequences exist between the human and the mouse NC16A domains of COL17. 
( b ) Generation of COL17-humanized mice by repeated crossing of heterozygous mouse  Col17 - 
knockout (m Col17  +/−  ) and  human COL17  +/+  Tg mice. ( c ) Skin detachment of the neonatal COL17- 
humanized mice is inducible by mild friction 48 h after the injection of BP-IgG. ( d ) Histologically, 
subepidermal blister formation ( arrowheads ) associated with linear deposition of human IgG 
( arrows ) and mouse C3 ( white arrowheads ) at the DEJ are observed 
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 This COL17-humanized BP mouse model is quite valuable not only for elucidat-
ing the pathomechanisms of BP but also for innovating disease-speciﬁ c therapies. 
We executed a therapeutic trial using human COL17 NC16A recombinant peptides. 
After the transfer of total IgG from BP patients, COL17-humanized mice were 
treated with a recombinant peptide composed of the NC16A domain. The treated 
mice showed markedly reduced blister formation [ 4 ]. In addition, we have devel-
oped a novel therapeutic strategy of treating BP by using the recombinant Fab frac-
tion of IgG monoclonal antibodies to COL17 to block the complement activation 
that would otherwise be induced by pathogenic autoantibodies [ 18 ]. We used phage 
display to generate recombinant Fab fragments of IgG monoclonal antibodies 
against the human COL17 NC16A domain from antibody repertoires of BP patients. 
Two recombinant Fab fragments showed marked ability to inhibit the binding of BP 
autoantibodies and to inhibit subsequent complement activation in vitro. In the 
in vivo experiments using the COL17-humanized BP mouse model, these recombi-
nant Fab fragments protected mice against BP-autoantibody-induced blistering dis-
ease [ 18 ]. Thus, the use of engineered Fab Abs to block pathogenic epitopes seems 
promising, and it may lead to disease-speciﬁ c treatments for BP. 
 Neonatal BP Model Induced by Maternally Transferred Abs 
to Human COL17 
 Using the COL17-humanized mouse, we developed another neonatal BP mouse 
model, which was induced by maternally transferred antibodies. When heterozy-
gous  mouse COL17 -deﬁ cient ( mCol17 +/− ) female mice are crossed with COL17- 
humanized ( hCOL17 +/+ ,  mCol17 −/− ) male mice, it is expected that 50 % of the pups 
will show the genotype of  human COL17 +/− ,  mouse Col17 −/− . We immunized  mouse 
COL17 +/− female mice with human COL17 and mated them with COL17-humanized 
( hCOL17 +/+ ,  mCol17 −/− ) male mice. As expected, the circulating anti-human COL17 
IgG antibodies that were produced by the immunized mother were transferred into 
the neonates through not only the placenta but also the milk, and half of the neo-
nates whose skin expressed human but not murine COL17 ( hCOL17 +/− ,  mCol17 −/− ) 
developed blisters associated with the histological and immunological features that 
are seen in BP patients [ 19 ]. This novel experimental system has some advantages: 
(1) the model does not require the technically difﬁ cult injection procedure; (2) the 
pathogenic IgG persists for longer than in conventional passive transfer models; and 
(3) the immune reaction totally depends on the murine immune system, even though 
the antigen is human COL17. 
 Active BP Model 
 To develop an active BP mouse model, we generated immunodeﬁ cient  Rag- 
2  −/−  / COL17-humanized mice by crossing COL17-humanized mice with  Rag-2  −/−  
mice. As a next step, we isolated splenocytes from the wild-type mice immunized 
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with human COL17 and adoptively transferred them into the  Rag-2  −/−  / COL17- 
humanized mice. Because these  Rag-2  −/−  / COL17-humanized mice had no mature T 
or B cells, they did not reject the transferred splenocytes. The transferred spleno-
cytes induced continuous production of anti-human COL17 IgG, and blistering dis-
ease occurred (Fig.  3 ) [ 20 ]. In that study, CD4 + T cells were proven to be crucial for 
the development of the BP phenotype, because the depletion of CD4 + T cells from 
immunized  splenocytes and the administration of cyclosporin A, a suppressant of 
T-cell function that works by inhibiting the production of IL-2 from the activated T 
cells, each signiﬁ cantly suppressed the development of pathogenic IgG and dimin-
ished the disease severity.
 Doxycycline-Inducible BP Model 
 We have produced different BP models using the COL17-humanized mice as 
described. In these COL17-humanized mice, the innate expression of human COL17 
eliminated all abnormal phenotypes observed in the  Col17 -knockout (m Col17  −/−  ) 
mice [ 4 ]. If the expression of human COL17 is induced after birth in the  Col17 - 
knockout (m Col17  −/−  ) mice, what kinds of phenotypes will appear? Blistering dis-
eases observed in adult  Col17 -knockout (m Col17  −/−  ) mice may be rescued by 
 Fig. 3  Generation of an active BP model. ( a )  Rag-2  −/−  COL17-humanized mice into which had 
been transferred splenocytes obtained from wild-type mice immunized by human COL17 protein. 
( b ) The treatment induces the continuous production of anti-human COL17 IgG and blister forma-
tion corresponding to BP. Histologically, subepidermal blister formation ( arrowheads ) associated 
with linear deposition of mouse IgG ( arrows ) at the DEJ are observed 
 
W. Nishie and H. Shimizu
115
neo-expression of human COL17 in the skin, but an immune reaction to human 
COL17 may occur. However, neo-expression of COL17 in adult  Col17 -knockout 
(m Col17  −/−  ) mice may induce Abs to human COL17, leading to blistering disease 
similar to BP (Fig.  4a ). We focused on using the Tet system that we commonly use 
to regulate expression of the gene of interest. By introducing transgenes including a 
reverse tetracycline-controlled transactivator (rtTA) and a pTRE vector with human 
COL17 cDNA, the administration of doxycycline induces the neo-expression of 
human COL17. In contrast, by incorporating a tetracycline-controlled transactivator 
(tTA) and a pTRE vector with human COL17 cDNA, the stable expression of human 
COL17 is expected to be suppressed by the administration of doxycycline. By 
in vitro studies using HEK 293 cells stably expressing pTRE-human COL17 and 
rtTA or tTA, we have found that the expression of human COL17 can be tightly 
regulated. In addition, the Tet-on system using rtTA showed less leaking expression 
of human COL17 (Fig.  4b ). On the basis of these results, we started to prepare two 
 Fig. 4  Strategy for the generation of a doxycycline-inducible BP model. ( a ) In vitro studies using 
HEK 293 cells stably expressing pTRE-human COL17 and rtTA or tTA show that the expression of 
human COL17 can be tightly regulated. A Tet-on system using rtTA results in less leaking expression 
of human COL17 compared with a Tet-off system ( arrows ). ( b ) Oral administration of doxycycline 
to pTRE-COL17, K14-rtTA, mouse COL17-null mice is expected to induce neo- expression of human 
COL17 in basal epidermal keratinocytes, which would induce autoimmunity to human COL17 
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different Tg mice expressing rtTA under keratin 14 (K14) promoter and pTRE- 
human COL17 cDNA. In the near future, we will obtain a novel BP model in which 
blistering disease can be initiated with only oral administration of doxycycline 
(Fig.  4a ).
 Perspectives 
 Recent studies using animal models have made considerable progress toward our 
understanding of the pathogenesis of BP as well as toward producing novel thera-
pies. To further advance our knowledge of BP pathomechanisms and to develop 
novel therapeutic strategies for BP, the establishment of an active, stable disease 
model is anticipated. 
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